Spots Global Cancer Trial Database for Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid Tumors
Official Title: Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetic and Primary Efficacy of PM1003 in Patients With Advanced Solid Tumors and Phase IIa Study to Evaluate the Primary Efficacy of PM1003 in Advanced Solid Tumors
Study ID: NCT05862831
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, open-lable, multicenter phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of PM1003 in the treatment of advanced solid tumors.
Detailed Description: PM1003 is a Bispecific Antibody Targeting PD-L1 and 4-1BB.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Cancer Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Shanghai Orient Hospital, Shanghai, , China
Contact Details
Name: Ye Guo
Affiliation: Shanghai Orient Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
